Author Archives: NeuroPerspective

Praying and Paying for Hope

The FDA’s approval of Sarepta Therapeutics’ eteplirsen for Duchenne Muscular Dystrophy (DMD) turned the spotlight on a decision process that has tapped fundamental fissures within the FDA and the scientific community, fractures that could reverberate in far larger scale in … Continue reading

Posted in Big Pharma, Biotech | Tagged , , | Leave a comment

Allergan Gets It Right

It had seemed for a while that the headlines only reinforced the common public perception that the pharma industry had devolved into a snake pit of self-centered greed. Led by the Three Horsemen of the Pharmapocalypse, Shkreli, Pearson, and Bresch … Continue reading

Posted in Big Pharma, Biotech | Tagged , , , , , , | Leave a comment

Academic Opioid Leapfrogs Field–Perhaps

Nature was the venue (8/18/16) for the publication of a paper from academic collaborators at UCSF, Stanford, UNC, Friedrich-Alexander-Universität Erlangen-Nürnberg, and Parelcus Medical University, a paper that reported the development of a highly refined, selective mu opioid agonist that–in animal … Continue reading

Posted in Biotech, Science | Tagged , , | Leave a comment

SAGE and PPD

SAGE Therapeutics’ remarkable run with tiny-n pilot studies as predictors of Phase II results continued when SAGE-547 separated remarkably well in a larger (albeit still very small, 21pt study) trial in severe Post-Partum Depression. A single injection provided remission of … Continue reading

Posted in Uncategorized | 1 Comment

Purdue’s Potemkin Village of Addiction-Prevention: Make Them Pay

The Los Angeles Times has published an appalling albeit impressive investigative piece (http://www.latimes.com/projects/la-me-oxycontin-part2/#nt=oft01a-1gp3; by Ruan, Girion, Glover) regarding Purdue Pharma’s handling of fraudulent Oxycontin prescriptions, and the part that this played in the opioid abuse crisis that has burgeoned in … Continue reading

Posted in Big Pharma, Biotech | Tagged , , , | Leave a comment

NIR in Cerebrum

NeuroPerspective’s editor and publisher, Harry Tracy PhD, was invited to provide a current assessment of the funding environment for therapeutics programs in the areas of Neurology/Psychiatry by Cerebrum, published by the Dana Foundation. That article–The Neuro Funding Rollercoaster–was released in … Continue reading

Posted in Biotech | 1 Comment

Acadia Outsources Compassion and Math

On their quarterly call, Acadia Pharmaceuticals announced the pricing for Nuplazid, freshly approved by the FDA for the treatment of Parkinsonian psychosis (PDP). The price has been set at $1950 per month, about $23,400 per year. A quick scan of … Continue reading

Posted in Big Pharma, BioFollies, Biotech | Tagged , , | 1 Comment